Also known as cancer of unknown origin or cancer of unknown primary.
Approximately 4% of all advanced cancers.
2-9% of all patients with cancer have a cancer of unknown primary.
Overall survival time median of approximately 6-12 months
Fourth most common cancer-related cause of death in patients of both sexes.
Reported to be the seventh or eighth most frequent category of malignant disease and the fourth most common cancer related cause of death in both sexes.
96% of cancers of in known primary have at least one genetic alteration, with a mean of 4 per tumor.
Potentially clinically relevant genomic alterations are identified in 85 percent of tumors.
Alterations in the RTK/Ras signaling pathway has been found in 72% is adenocarcinomas of unknown primary but only 39% of non-adenocarcinoma of unknown primary.
Cancer of unknown origin is the seventh most common malignancy.
The lesion arises when metastases each detectable size faster than the primary tumor.
Primary can be identified in only 30-82% of cases at autopsy.
About 80,000 cases annually in the US.
Most cases are limited to epithelial and undifferentiated cancers.
Median survival of approximately 8-12months: The overall survival of cancer of unknown primary patients has not improved in over 30 years.
Patients with isolated nodal metastases have a better prognosis with appropriate therapy.
Metastatic adenocarcinoma represents the most common histology in patients with cancer of unknown primary, with lung or pancreatic as the most common source.
Approximately two thirds of patients with cancer of unknown origin are adenocarcinomas with mucin production, tubule formation, and immunohistochemistry findings of adenocarcinoma.
About one third of cancers of unknown origin are a mix of non-adenocarcinoma including squamous cell carcinoma, neuroendocrine carcinoma, small cell and large cell undifferentiated carcinomas.
With adenocarcinoma the median survival is about 3 months.
In women with disseminated peritoneal carcinomatosis the primary tumor usually originates in the ovary.
Adenocarcinoma to the axilla in men the lung, GI and GU tracts are the main considerations for primary lesion.
Adenocarcinoma to the axilla in a woman suggests breast cancer as the primary lesion.
Squamous cell cancer to cervical nodes head and neck cancers should be suspected as the primary lesion.
Squamous cell carcinoma to the neck has a 5-year survival rate of 30-50%.
Involving the head and neck-metastases to the cervical lymph nodes is seen in approximately 3-5% of cases of head and neck cancers.
Involving the head and neck-most cervical lymph nodes arise from upper aerodigestive tract sites, but may come from the thyroid, lung or esophagus.
Involving the head and neck-squamous cell carcinoma represents about 90% of metastatic lesions to the cervical lymph nodes with unknown primary tumors-melanoma, adenocarcinoma and lymphoma account for the remaining lesions.
Involving the head and neck-incidence in Denmark found to be 0.34 per 100,000 population (Grau).
Involving the head and neck-fewer than 60% of squamous cell cancers of the neck of unknown origin are identified as to the primary lesion.
Unknown primary cancers of the head and neck originate mostly from the palatine tonsil, base of the tongue or the nasopharynx.
Unknown primary cancers of the head and neck require an evaluation by a head and neck specialist, with examination of the head and neck skin, and endoscopy of the nasopharynx, or pharynx, larynx, and hypopharynx with palpation of the tonsil and base of tongue.
Presently, there is no consensus on the diagnostic tests required for all patients at the time of clinical presentation.
Unknown primary cancers of the head and neck-evaluation will reveal the primary in 52-55% of cases (Jones).
The primary may be too small to detect or it may disappear after metastasizing.
Aneuploidy identified in 70% of such lesions
No unique chromosomal or molecular abnormalities have been identified.
High degree of expression of VEGF in all cases.
Most widely accessible diagnostic scanning test is the PET scan.
Immunohistochemistry marker stains and gene expression/molecular profiling assays have led to improvements in the evaluation of such tumors and allows treatment with more specific agents with better survival.